{"id":440839,"date":"2021-02-22T09:33:21","date_gmt":"2021-02-22T14:33:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=440839"},"modified":"2021-02-22T09:33:21","modified_gmt":"2021-02-22T14:33:21","slug":"new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-well-beyond-acute-disease-into-chronic-phase","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-well-beyond-acute-disease-into-chronic-phase\/","title":{"rendered":"New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase"},"content":{"rendered":"

<\/p>\n

New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase<\/b><\/p>\n

— Results presented at NANOS 2021 Annual Meeting show persistent burden on physical and mental health —<\/i><\/p>\n

DUBLIN–(BUSINESS WIRE<\/a>)–
\nHorizon Therapeutics plc (Nasdaq: HZNP) today announced results of a new Thyroid Eye Disease (TED) quality of life (QOL) assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (active) phase of the disease, but that this burden continues well into the chronic (inactive) phase.\n<\/p>\n

\nTED is a rare autoimmune disease that begins with an acute phase where inflammatory signs and symptoms, such as eye pain, swelling, proptosis (eye bulging) and diplopia (double vision), progress over time. The disease then changes to a chronic phase where inflammation may slow or stop, but signs and symptoms often remain.\n<\/p>\n

\n\u201cThe results of this survey challenge our traditional understanding of the phases of Thyroid Eye Disease and its impact on patients,\u201d said Kimberly Cockerham, M.D., adjunct clinical associate professor, Department of Ophthalmology, Stanford University School of Medicine and primary author of the study. \u201cA common belief is that once a patient progresses to the chronic phase of the disease, symptoms diminish and the impact on quality of life improves. But in this survey, the quality of life of patients with chronic Thyroid Eye Disease was reported to be significantly impaired and nearly identical to scores seen in clinical trials of patients with acute, moderate-to-severe disease.\u201d\n<\/p>\n

\nThe online survey assessed 100 patients with chronic TED at various levels of severity. Patient characteristics and TED parameters were measured both at the time of diagnosis and after being told their TED was in the chronic phase. QOL was measured using the Graves\u2019 Ophthalmopathy Quality of Life Questionnaire (GO-QOL) instrument. Scores range from 0 (worst) to 100 (best), with a score of 90-100 considered normal. Scores were stratified as low (less than 50), middle (50-75) and high (greater than 75).\n<\/p>\n

Key findings include the following:<\/b><\/p>\n